T0080
Based on 1 Customer Validation
T0080 is a central nervous system-penetrant FPR1 inhibitor. By functionally blocking the FPR1 signaling pathway, T0080 effectively reduces neutrophil infiltration into ischemic brain tissue and maintains the integrity of the blood-brain barrier. T0080 alleviates tPA-associated hemorrhagic transformation, inhibits demyelination responses and the expression of NOX2. T0080 also possesses anti-apoptotic (apoptosis) and anti-inflammatory properties, thereby protecting myelin and reducing neurological deficits. T0080 is widely used in studies related to ischemic stroke complicated by hemorrhagic transformation after tPA thrombolysis, as well as multiple sclerosis.
Nur für Forschungszwecke. Wir verkaufen nicht an Patienten.
- Reinheit: 99.94%
- CAS. Nr.: 2785323-68-2
- Formel: C24H22F3N3O3
- Molecular Weight:457.44
-
Speicherung:Powder -20°C, 3 years , 4°C, 2 years ; In solvent -80°C, 6 months , -20°C, 1 month
To place orders, for customer services and technical support, please contact: MedChemExpress USA
Tel: 609-228-6898 E-mail: [email protected] [email protected]
-
Biologische Aktivität
-
Chemical Information
-
Lösungsmittel & Löslichkeit
- Reinheit & Dokumentation
- Verweise
-
Help & FAQs
-
Apoptosis Compound Library
HY-L003
-
GPCR/G Protein Compound Library
HY-L006
-
Immunology/Inflammation Compound Library
HY-L007
-
Anti-Cardiovascular Disease Compound Library
HY-L046
-
Pyroptosis Compound Library
HY-L059
-
Membrane Protein-targeted Compound Library
HY-L149
-
Membrane Receptor-targeted Compound Library
HY-L150
-
Cell Death Library
HY-L162
-
Bioactive Compound Library Max
HY-L181
-
MCE Bioactive Compound Library
HY-L001V
-
Bioactive Compound Library
HY-L001
-
Non-Alcoholic Fatty Liver Disease (NAFLD) Compound Library
HY-L199
-
High-Throughput Bioactive Compound Library
HY-L205
-
Lactylation Compound Library
HY-L249
Biologische Aktivität
T0080 (5 µM; 2-6 h) suppresses activation of primary mouse neutrophils isolated from pMCAO mice, reduces their migration across bEnd.3 endothelial cell monolayers, and preserves bEnd.3 cell tight junction integrity and viability in vitro[1].
T0080 reduces mtFP-induced apoptosis in human induced pluripotent stem cell-derived neurons and oligodendrocytes cocultured with microglia[2].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
T0080 (5 mg/kg; i.p.; single dose; 3 h post-tMCAO at time of tPA thrombolysis) significantly reduces tPA-induced hemorrhagic transformation and neurological deficits in the tMCAO mouse model[1].
T0080 (5 mg/kg; i.p.; daily) reduces clinical deficits, demyelination, CNS immune cell infiltration, and spinal cord inflammation in C57BL/6 EAE mice[2].
T0080 (5 mg/kg; i.p.; daily) reduces clinical deficits, demyelination, and axonal loss in the secondary progressive NOD-EAE mouse model of MS[2].
T0080 (5 mg/kg; i.p.; daily) reduces myelin loss in the cuprizone-induced demyelination mouse model of MS[2].
T0080 (5 mg/kg; i.p.; daily) reduces human FPR1-expressing microglia in humanized FPR1 transgenic EAE mice[2].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Animal Model:C57BL/6 mice with Ischemic stroke (male, 8-10 weeks old, photothrombotic middle cerebral artery occlusion model)[1]
-
Dosage:5 mg/kg (1 h post-pMCAO); 5 mg/kg (2 h post-pMCAO)
-
Administration:i.p.; single dose
-
Result:Significantly reduced modified Neurological Severity Score (mNSS) values compared to vehicle controls.
Increased rotarod test performance times compared to vehicle controls.
Significantly decreased cerebral hemoglobin content and Evans blue extravasation in the ischemic hemisphere compared to vehicle controls.
Reduced brain infiltration of Ly6G+ neutrophils compared to vehicle controls.
Increased relative fluorescence intensity of tight junction proteins Claudin-5 and ZO-1 compared to vehicle controls.
Chemical Information
-
CAS. Nr. 2785323-68-2
-
Appearance Solid
-
Molecular Weight 457.44
-
Formel C24H22F3N3O3
-
Color White to off-white
-
SMILES
OC1=CC=C(C)C=C1C2=C(C(C3=CC=C(C(F)(F)F)C=C3)N(C4CCOCC4)C5=O)C5=NN2
-
Versand
Room temperature in continental US; may vary elsewhere.
-
Speicherung
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month
Lösungsmittel & Löslichkeit
DMSO : 100 mg/mL (218.61 mM; Need ultrasonic; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month. When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month. When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
Konzentration (Stammlösung) × Volumen (Stammlösung) = Konzentration (Ziellösung) × Volumen (Ziellösung)
Select the appropriate dissolution method based on your experimental animal and administration route.
- For the following dissolution methods, please ensure to first prepare a clear stock solution using an In Vitro approach and then sequentially add co-solvents:
- To ensure reliable experimental results, the clarified stock solution can be appropriately stored based on storage conditions. As for the working solution for In Vivo experiments, it is recommended to prepare freshly and use it on the same day.
- The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.
Add each solvent one by one: 10% DMSO 40% PEG300 5% Tween-80 45% Saline
Solubility: ≥ 2.5 mg/mL (5.47 mM); Clear solution
This protocol yields a clear solution of ≥ 2.5 mg/mL (saturation unknown).
Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 400 μL PEG300, and mix evenly; then add 50 μL Tween-80 and mix evenly; then add 450 μL Saline to adjust the volume to 1 mL.
Preparation of Saline: Dissolve 0.9 g sodium chloride in ddH₂O and dilute to 100 mL to obtain a clear Saline solution.
Please enter the basic information of animal experiments:
-
-
-
-
Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.
Please enter your animal formula composition:
-
%DMSO +
Recommended: Keep the proportion of DMSO in working solution below 2% if your animal is weak.
-
%+
-
+%Tween-80 + +
-
%Saline +
The co-solvents required include: DMSO, . All of co-solvents are available by MedChemExpress (MCE). , Tween 80. All of co-solvents are available by MedChemExpress (MCE).
Working solution concentration: 0.22 mg/mL
Method for preparing stock solution: mg drug dissolved in μL DMSO. Stock solution concentration: mg/mL.
1. Take μL DMSO stock solution;
2. Add μL .
μL , mix evenly;
3. Then add μL Tween 80, mix evenly;
4. Then add μL
Please ensure that the stock solution in the first step is dissolved to a clear state, and add co-solvents in sequence. You can use ultrasonic heating (ultrasonic cleaner, recommended frequency 20-40 kHz), vortexing, etc. to assist dissolution.
Reinheit & Dokumentation
-
Data Sheet (282 KB)
-
SDS (251 KB)
- English - EN (251 KB)
- Français - FR (251 KB)
- Deutsch - DE (251 KB)
- Norwegian - NO (251 KB)
- Español - ES (251 KB)
- Swedish - SV (251 KB)
- Italian - IT (251 KB)
- Korean - KR (251 KB)
- Portuguese - PT (251 KB)
-
Handling Instructions (2659 KB)
Verweise
[1]. Lv J, et al. Formyl peptide receptor 1 signaling exacerbates hemorrhagic transformation following tPA thrombolysis in mice. J Cereb Blood Flow Metab. 2026;46(3):682-694. [Content Brief]
[2]. Li Y, et al. Targeting formyl peptide receptor 1 reduces brain inflammation and neurodegeneration. Science. 2025;390(6774):eadq1177. [Content Brief]
Complete Stock Solution Preparation Table
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month. When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
| Optional Solvent | Concentration Solvent Mass | 1 mg | 5 mg | 10 mg | 25 mg |
|---|---|---|---|---|---|
| DMSO | 1 mM | 2.1861 mL | 10.9304 mL | 21.8608 mL | 54.6520 mL |
| 5 mM | 0.4372 mL | 2.1861 mL | 4.3722 mL | 10.9304 mL | |
| 10 mM | 0.2186 mL | 1.0930 mL | 2.1861 mL | 5.4652 mL | |
| 15 mM | 0.1457 mL | 0.7287 mL | 1.4574 mL | 3.6435 mL | |
| 20 mM | 0.1093 mL | 0.5465 mL | 1.0930 mL | 2.7326 mL | |
| 25 mM | 0.0874 mL | 0.4372 mL | 0.8744 mL | 2.1861 mL | |
| 30 mM | 0.0729 mL | 0.3643 mL | 0.7287 mL | 1.8217 mL | |
| 40 mM | 0.0547 mL | 0.2733 mL | 0.5465 mL | 1.3663 mL | |
| 50 mM | 0.0437 mL | 0.2186 mL | 0.4372 mL | 1.0930 mL | |
| 60 mM | 0.0364 mL | 0.1822 mL | 0.3643 mL | 0.9109 mL | |
| 80 mM | 0.0273 mL | 0.1366 mL | 0.2733 mL | 0.6831 mL | |
| 100 mM | 0.0219 mL | 0.1093 mL | 0.2186 mL | 0.5465 mL |
T0080 Related Classifications
HY-173591 Related Classifications
Powered by Bioz
- T0080
- 2785323-68-2
- T 0080
- T-0080
- Formyl Peptide Receptor (FPR)
- Apoptosis
- Formyl peptide receptor 1
- human induced pluripotent stem cell-derived neurons
- oligodendrocytes
- multiple sclerosis
- ischemic stroke
- bEnd.3 endothelial cell
- primary mouse microglia
- C57BL/6 EAE mice
- blood-brain barrier
- neutrophil
- Inhibitor
- inhibitor
- inhibit